{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:19:34Z","timestamp":1780431574245,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Tianjin Province","award":["21JCYBJC01160"],"award-info":[{"award-number":["21JCYBJC01160"]}]},{"name":"the Science and Technology Innovation 2030\u2014Major Project","award":["2021ZD0201805"],"award-info":[{"award-number":["2021ZD0201805"]}]},{"name":"the Tianjin Key Medical Discipline (Specialty) Construction Project","award":["TJYXZDXK-004A"],"award-info":[{"award-number":["TJYXZDXK-004A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-83919-x","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T19:52:03Z","timestamp":1742586723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A cytometric bead array for the measurement of plasma biomarker levels in patients with Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Ye","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyan","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengya","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"83919_CR1","doi-asserted-by":"publisher","unstructured":"Alzheimer\u2019s, A. Alzheimer\u2019s disease facts and figures. Alzheimers Dement 12, 459\u2013509, doi: (2016). https:\/\/doi.org\/10.1016\/j.jalz.2016.03.001 (2016).","DOI":"10.1016\/j.jalz.2016.03.001"},{"key":"83919_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nrd3115","volume":"9","author":"H Hampel","year":"2010","unstructured":"Hampel, H. et al. Biomarkers for Alzheimer\u2019s disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 9, 560\u2013574. https:\/\/doi.org\/10.1038\/nrd3115 (2010).","journal-title":"Nat. Rev. Drug Discov"},{"key":"83919_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018 (2018).","journal-title":"Alzheimers Dement."},{"key":"83919_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens, P. et al. Alzheimer\u2019s disease. Lancet 388, 505\u2013517. https:\/\/doi.org\/10.1016\/S0140-6736(15)01124-1 (2016).","journal-title":"Lancet"},{"key":"83919_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/alzrt162","volume":"5","author":"JB Toledo","year":"2013","unstructured":"Toledo, J. B., Shaw, L. M. & Trojanowski, J. Q. Plasma amyloid beta measurements - a desired but elusive Alzheimer\u2019s disease biomarker. Alzheimers Res. Ther. 5, 8. https:\/\/doi.org\/10.1186\/alzrt162 (2013).","journal-title":"Alzheimers Res. Ther."},{"key":"83919_CR6","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze, S. et al. Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease. Sci. Rep. 6, 26801. https:\/\/doi.org\/10.1038\/srep26801 (2016).","journal-title":"Sci. Rep."},{"key":"83919_CR7","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk, I. M. W. et al. Plasma amyloid as Prescreener for the Earliest Alzheimer pathological changes. Ann. Neurol. 84, 648\u2013658. https:\/\/doi.org\/10.1002\/ana.25334 (2018).","journal-title":"Ann. Neurol."},{"key":"83919_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422\u2013433. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5 (2020).","journal-title":"Lancet Neurol."},{"key":"83919_CR9","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/alz.12332","volume":"17","author":"JR Chong","year":"2021","unstructured":"Chong, J. R. et al. Plasma P-tau181 to Abeta42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer\u2019s disease patients with concomitant cerebrovascular disease. Alzheimers Dement. 17, 1649\u20131662. https:\/\/doi.org\/10.1002\/alz.12332 (2021).","journal-title":"Alzheimers Dement."},{"key":"83919_CR10","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00221-018-5210-x","volume":"236","author":"J Vogelgsang","year":"2018","unstructured":"Vogelgsang, J. et al. Multiplex immunoassay measurement of amyloid-beta(42) to amyloid-beta(40) ratio in plasma discriminates between dementia due to Alzheimer\u2019s disease and dementia not due to Alzheimer\u2019s disease. Exp. Brain Res. 236, 1241\u20131250. https:\/\/doi.org\/10.1007\/s00221-018-5210-x (2018).","journal-title":"Exp. Brain Res."},{"key":"83919_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat. Med. 26, 379\u2013386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1 (2020).","journal-title":"Nat. Med."},{"key":"83919_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat. Med. 26, 387\u2013397. https:\/\/doi.org\/10.1038\/s41591-020-0762-2 (2020).","journal-title":"Nat. Med."},{"key":"83919_CR13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14, 989\u2013997. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.013 (2018).","journal-title":"Alzheimers Dement."},{"key":"83919_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura, A. et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature 554, 249\u2013254. https:\/\/doi.org\/10.1038\/nature25456 (2018).","journal-title":"Nature"},{"key":"83919_CR15","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/brain\/awaa403","volume":"144","author":"A Keshavan","year":"2021","unstructured":"Keshavan, A. et al. Population-based blood screening for preclinical Alzheimer\u2019s disease in a British birth cohort at age 70. Brain 144, 434\u2013449. https:\/\/doi.org\/10.1093\/brain\/awaa403 (2021).","journal-title":"Brain"},{"key":"83919_CR16","doi-asserted-by":"publisher","unstructured":"Barthelemy, N. R., Horie, K., Sato, C. & Bateman, R. J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J. Exp. Med. 217 https:\/\/doi.org\/10.1084\/jem.20200861 (2020).","DOI":"10.1084\/jem.20200861"},{"key":"83919_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clim.2003.11.017","volume":"110","author":"E Morgan","year":"2004","unstructured":"Morgan, E. et al. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin. Immunol. 110, 252\u2013266. https:\/\/doi.org\/10.1016\/j.clim.2003.11.017 (2004).","journal-title":"Clin. Immunol."},{"key":"83919_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131\u2013144. https:\/\/doi.org\/10.1038\/nrneurol.2010.4 (2010).","journal-title":"Nat. Rev. Neurol."},{"key":"83919_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack, C. R. Jr. et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207\u2013216. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0 (2013).","journal-title":"Lancet Neurol."},{"key":"83919_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12987-017-0062-5","volume":"14","author":"Z Chen","year":"2017","unstructured":"Chen, Z. et al. Cerebrospinal fluid Abeta42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis. Fluids Barriers CNS. 14, 13. https:\/\/doi.org\/10.1186\/s12987-017-0062-5 (2017).","journal-title":"Fluids Barriers CNS"},{"key":"83919_CR21","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.3233\/JAD-170784","volume":"62","author":"CE Teunissen","year":"2018","unstructured":"Teunissen, C. E. et al. Plasma amyloid-beta (Abeta42) correlates with cerebrospinal fluid Abeta42 in Alzheimer\u2019s Disease. J. Alzheimers Dis. 62, 1857\u20131863. https:\/\/doi.org\/10.3233\/JAD-170784 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"83919_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00401-011-0861-8","volume":"122","author":"JB Toledo","year":"2011","unstructured":"Toledo, J. B. et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 122, 401\u2013413. https:\/\/doi.org\/10.1007\/s00401-011-0861-8 (2011).","journal-title":"Acta Neuropathol."},{"key":"83919_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-015-1477-1","volume":"130","author":"Y Xiang","year":"2015","unstructured":"Xiang, Y. et al. Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer\u2019s disease. Acta Neuropathol. 130, 487\u2013499. https:\/\/doi.org\/10.1007\/s00401-015-1477-1 (2015).","journal-title":"Acta Neuropathol."},{"key":"83919_CR24","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1038\/s41380-021-01073-6","volume":"26","author":"DY Tian","year":"2021","unstructured":"Tian, D. Y. et al. Physiological clearance of amyloid-beta by the kidney and its therapeutic potential for Alzheimer\u2019s disease. Mol. Psychiatry. 26, 6074\u20136082. https:\/\/doi.org\/10.1038\/s41380-021-01073-6 (2021).","journal-title":"Mol. Psychiatry"},{"key":"83919_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","volume":"26","author":"TK Karikari","year":"2021","unstructured":"Karikari, T. K. et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative. Mol. Psychiatry. 26, 429\u2013442. https:\/\/doi.org\/10.1038\/s41380-020-00923-z (2021).","journal-title":"Mol. Psychiatry"},{"key":"83919_CR26","doi-asserted-by":"publisher","first-page":"fcab073","DOI":"10.1093\/braincomms\/fcab073","volume":"3","author":"FZ Lussier","year":"2021","unstructured":"Lussier, F. Z. et al. Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. Brain Commun. 3, fcab073. https:\/\/doi.org\/10.1093\/braincomms\/fcab073 (2021).","journal-title":"Brain Commun."},{"key":"83919_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/brain\/awaa399","volume":"144","author":"A Moscoso","year":"2021","unstructured":"Moscoso, A. et al. Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum. Brain 144, 325\u2013339. https:\/\/doi.org\/10.1093\/brain\/awaa399 (2021).","journal-title":"Brain"},{"key":"83919_CR28","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/alz.12283","volume":"17","author":"J Simren","year":"2021","unstructured":"Simren, J. et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 17, 1145\u20131156. https:\/\/doi.org\/10.1002\/alz.12283 (2021).","journal-title":"Alzheimers Dement."},{"key":"83919_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13195-021-00805-8","volume":"13","author":"C Clark","year":"2021","unstructured":"Clark, C. et al. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer\u2019s disease pathology and clinical disease progression. Alzheimers Res. Ther. 13, 65. https:\/\/doi.org\/10.1186\/s13195-021-00805-8 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"83919_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jid.2015.36","volume":"135","author":"S Khalifian","year":"2015","unstructured":"Khalifian, S., Raimondi, G. & Brandacher, G. The use of luminex assays to measure cytokines. J. Invest. Dermatol. 135, 1\u20135. https:\/\/doi.org\/10.1038\/jid.2015.36 (2015).","journal-title":"J. Invest. Dermatol."},{"key":"83919_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jim.2011.06.033","volume":"372","author":"D Dabitao","year":"2011","unstructured":"Dabitao, D., Margolick, J. B., Lopez, J. & Bream, J. H. Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the cytometric bead array. J. Immunol. Methods. 372, 71\u201377. https:\/\/doi.org\/10.1016\/j.jim.2011.06.033 (2011).","journal-title":"J. Immunol. Methods"},{"key":"83919_CR32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/gerona\/63.8.879","volume":"63","author":"SX Leng","year":"2008","unstructured":"Leng, S. X. et al. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J. Gerontol. Biol. Sci. Med. Sci. 63, 879\u2013884. https:\/\/doi.org\/10.1093\/gerona\/63.8.879 (2008).","journal-title":"J. Gerontol. Biol. Sci. Med. Sci."},{"key":"83919_CR33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barthelemy","year":"2020","unstructured":"Barthelemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat. Med. 26, 398\u2013407. https:\/\/doi.org\/10.1038\/s41591-020-0781-z (2020).","journal-title":"Nat. Med."},{"key":"83919_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze, S. et al. Associations of plasma Phospho-Tau217 levels with tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol. 78, 149\u2013156. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4201 (2021).","journal-title":"JAMA Neurol."},{"key":"83919_CR35","doi-asserted-by":"publisher","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. Abeta deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer\u2019s disease. Sci. Adv. 6, eaaz2387. https:\/\/doi.org\/10.1126\/sciadv.aaz2387 (2020).","journal-title":"Sci. Adv."},{"key":"83919_CR36","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault, J. et al. Association of phosphorylated tau biomarkers with amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. 80, 188\u2013199. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4485 (2023).","journal-title":"JAMA Neurol."},{"key":"83919_CR37","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative disorders. JAMA 324, 772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134 (2020).","journal-title":"JAMA"},{"key":"83919_CR38","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s43587-023-00405-1","volume":"3","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya, L. et al. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nat. Aging. 3, 661\u2013669. https:\/\/doi.org\/10.1038\/s43587-023-00405-1 (2023).","journal-title":"Nat. Aging"},{"key":"83919_CR39","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat. Med. 29, 1954\u20131963. https:\/\/doi.org\/10.1038\/s41591-023-02443-z (2023).","journal-title":"Nat. Med."},{"key":"83919_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","volume":"256","author":"B Winblad","year":"2004","unstructured":"Winblad, B. et al. Mild cognitive impairment\u2013beyond controversies, towards a consensus: report of the International Working Group on mild cognitive impairment. J. Intern. Med. 256, 240\u2013246. https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01380.x (2004).","journal-title":"J. Intern. Med."},{"key":"83919_CR41","doi-asserted-by":"crossref","unstructured":"Arlington, V. A. & American Psychiatric Association. : Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. (2013).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"83919_CR42","first-page":"1959","volume":"46","author":"BJ Lopresti","year":"2005","unstructured":"Lopresti, B. J. et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J. Nucl. Med. 46, 1959\u20131972 (2005).","journal-title":"J. Nucl. Med."},{"key":"83919_CR43","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/mp.2017.146","volume":"23","author":"K Goozee","year":"2018","unstructured":"Goozee, K. et al. Elevated plasma ferritin in elderly individuals with high neocortical amyloid-beta load. Mol. Psychiatry. 23, 1807\u20131812. https:\/\/doi.org\/10.1038\/mp.2017.146 (2018).","journal-title":"Mol. Psychiatry"},{"key":"83919_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.dadm.2017.04.007","volume":"8","author":"S Engelborghs","year":"2017","unstructured":"Engelborghs, S. et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement. (Amst). 8, 111\u2013126. https:\/\/doi.org\/10.1016\/j.dadm.2017.04.007 (2017).","journal-title":"Alzheimers Dement. (Amst)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83919-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83919-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83919-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T19:52:17Z","timestamp":1742586737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83919-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["83919"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83919-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9767"}}